We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the latest close session, Eli Lilly (LLY - Free Report) was up +2.44% at $839.87. The stock exceeded the S&P 500, which registered a gain of 0.01% for the day. Elsewhere, the Dow gained 0.51%, while the tech-heavy Nasdaq lost 0.28%.
Heading into today, shares of the drugmaker had gained 10.36% over the past month, outpacing the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83%.
The upcoming earnings release of Eli Lilly will be of great interest to investors. The company's earnings report is expected on October 30, 2025. The company is predicted to post an EPS of $6.42, indicating a 444.07% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $16.05 billion, indicating a 40.32% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $23.03 per share and a revenue of $61.81 billion, demonstrating changes of +77.29% and +37.22%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Eli Lilly. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Eli Lilly presently features a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is currently trading at a Forward P/E ratio of 35.6. This expresses a premium compared to the average Forward P/E of 14.84 of its industry.
Investors should also note that LLY has a PEG ratio of 1.15 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.61 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 33, which puts it in the top 14% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow LLY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Laps the Stock Market: Here's Why
In the latest close session, Eli Lilly (LLY - Free Report) was up +2.44% at $839.87. The stock exceeded the S&P 500, which registered a gain of 0.01% for the day. Elsewhere, the Dow gained 0.51%, while the tech-heavy Nasdaq lost 0.28%.
Heading into today, shares of the drugmaker had gained 10.36% over the past month, outpacing the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83%.
The upcoming earnings release of Eli Lilly will be of great interest to investors. The company's earnings report is expected on October 30, 2025. The company is predicted to post an EPS of $6.42, indicating a 444.07% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $16.05 billion, indicating a 40.32% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $23.03 per share and a revenue of $61.81 billion, demonstrating changes of +77.29% and +37.22%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Eli Lilly. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Eli Lilly presently features a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is currently trading at a Forward P/E ratio of 35.6. This expresses a premium compared to the average Forward P/E of 14.84 of its industry.
Investors should also note that LLY has a PEG ratio of 1.15 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.61 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 33, which puts it in the top 14% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow LLY in the coming trading sessions, be sure to utilize Zacks.com.